Biotechnology and Genetic Engineering
Total Page:16
File Type:pdf, Size:1020Kb
GLOBAL ISSUES BIOTECHNOLOGY AND GENETIC ENGINEERING GLOBAL ISSUES BIOTECHNOLOGY AND GENETIC ENGINEERING Kathy Wilson Peacock Foreword by Charles Hagedorn, Ph.D. Professor, Environmental Microbiology, Virginia Tech GLOBAL ISSUES: BioTECHNologY AND GENETIC ENgiNeeRING Copyright © 2010 by Infobase Publishing All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval systems, without permission in writing from the publisher. For information contact: Facts On File, Inc. An imprint of Infobase Publishing 132 West 31st Street New York NY 10001 Library of Congress Cataloging-in-Publication Data Peacock, Kathy Wilson. Biotechnology and genetic engineering / Kathy Wilson Peacock; foreword by Charles Hagedorn. p.; cm. — (Global issues) Includes bibliographical references and index. ISBN 978-0-8160-7784-7 (alk. paper) 1. Biotechnology—Popular works. 2. Genetic engineering—Popular works. I. Title. II. Series: Global issues (Facts on File, Inc.) [DNLM: 1. Biotechnology. 2. Genetic Engineering. 3. Organisms, Genetically Modified—genetics. QU 450 P352b 2010] TP248.215.P43 2010 660.6—dc22 2009025794 Facts On File books are available at special discounts when purchased in bulk quantities for businesses, associations, institutions, or sales promotions. Please call our Special Sales Department in New York at (212) 967-8800 or (800) 322-8755. You can find Facts On File on the World Wide Web at http://www.factsonfile.com Text design by Erika K. Arroyo Illustrations by Dale Williams Composition by Mary Susan Ryan-Flynn Cover printed by Art Print, Taylor, Pa. Book printed and bound by Maple Press, York, Pa. Date printed: May 2010 Printed in the United States of America This book is printed on acid-free paper. CONTENTSj1 Foreword by Charles Hagedornâ vii List of Acronymsâ xi List of Maps and Graphsâ xv PART I: At Issue Chapter 1: Introductionâ 3 The Issueâ 4 The Challengesâ 19 International Historyâ 33 Chapter 2: Focus on the United Statesâ 54 Current Situationâ 54 Historyâ 63 Counterstrategiesâ 77 Chapter 3: Global Perspectivesâ 85 Introductionâ 85 Icelandâ 85 Singaporeâ 86 Great Britainâ 88 Japanâ 90 Indiaâ 97 Germanyâ 104 South Africaâ 110 Conclusionâ 120 PART II: Primary Sources Chapter 4: United States Documentsâ 129 Chapter 5: International Documentsâ 170 Japanâ 192 Indiaâ 197 Germanyâ 202 South Africaâ 209 PART III: Research Tools Chapter 6: How to Research Biotechnologyâ 215 Getting Startedâ 215 Using Sources Effectivelyâ 223 Chapter 7: Facts and Figuresâ 229 Chapter 8: Key Players A to Zâ 239 Chapter 9: Organizations and Agenciesâ 252 Chapter 10: Annotated Bibliographyâ 267 Bioethicsâ 267 Biotechnology and Agricultureâ 273 Biotechnology, Medicine, â Stem Cell Research, and Biowarfareâ 284 Genetic Engineering/ â Human Genome Projectâ 289 Biotechnology History and Biographyâ 295 Chronologyâ 302 Glossaryâ 322 Indexâ 333 j Foreword In September 1992, the University of California, San Francisco and the Exploratorium, housed in San Francisco’s Palace of Fine Arts, presented a public symposium entitled “Winding Your Way through DNA.” This pro- gram was designed to educate the public and to encourage a dialogue about the scientific possibilities and associated problems with recombinant DNA technology. Following the symposium, a team of high school and college teachers, ethicists, historians, and scientists created a series of documents and videos that they hoped would establish a long-term discussion about this technology and the ethical, legal, and societal issues that have emerged since its inception. This symposium fully recognized that the first century of the new millennium would belong to biotechnology, among all the biologi- cal sciences, and that biotechnology could bring unprecedented advances in human and animal health, agriculture and food production, manufacturing, and sustainable environmental management. Also recognized was the need to exercise caution and judgment in its application to ensure that the poten- tial risks to human health and the environment arising from the commercial use of genetically modified organisms in food production were properly managed. Such management included continuous assessment of biotech- nology programs, establishment of suitable regulatory systems to oversee biotechnology products, and efforts to increase public awareness and accep- tance of these products. What the symposium participants could not have foreseen in 1992 was the incredible speed by which biotechnology would develop. This speed resulted in more than 115 million hectares of biotechnology crops in 2007, compared to none in 1992; completion of the Human Genome Project in 2003, two years ahead of schedule and under budget; and progress in technologies such as cloning, stem cell research, processes to increase longevity, intelligence, and physical abilities—the potential for human en- hancement—termed by many as the most fundamental social and political vii Biotechnology and Genetic Engineering issue facing the world today. The 1992 symposium participants also could not have foreseen how controversial every development in biotechnology would become: that efforts to increase public understanding would result in whole societies rejecting certain technologies (for example, the Euro- pean Union ban on importation of genetically engineered food products); that regulatory systems would vary so widely from stringent in the United States and Europe to almost nonexistent in many developing countries; that growth in food production would remain largely within developed and wealthy countries; and that developments in the potential for human en- hancement would provide hope to many but dread and horror to others. Biotechnology dates from the dawn of civilization, where the earliest farmers selected edible plants to grow as crops and saved some of the seeds for the next season, and domesticated cattle, pigs, sheep, and goats. Over the years, farmers bred both the plants and animals they liked and learned how to best produce them with irrigation and weed control for plants and grow- ing grain and forages for the animals. Early civilizations around the globe also used yeast to make alcohol and bread—yeast being a living microorganism (a fungus)—long before its role in fermentation was understood. One of the primary goals of biotechnology is to feed the world’s 6 billion people, but there is substantial disagreement over the best way to accomplish this. Some people think genetically altered crops are the best answer because they allow farmers to grow more food less expensively than ever before. Others see these crops as being available only in wealthy countries and not accessible to much of the developing world, places where such crops would do the most good (for example, 73 percent of all biotechnology crops are grown in the United States, Canada, and Argentina). Most of the controversy surrounding biotechnology involves drawing distinctions between what is acceptable and what is not. Is it wrong to modify germ-line cells (those that can be passed on to future generations) to ensure that a child has blue eyes? Is that more wrong than aborting a fetus with grave medical defects? Clearly, people have differing ideas about where such lines should be drawn. In practice, a double standard is sometimes evident. For example, growth hormones are illegal in the United States for bodybuilders and athletes, but the U.S. meat supply is heavily dependent on these same hormones to promote rapid growth in food animals. The development of biotechnology in the United States has been similar to that of other countries that have embraced it. The earliest policies were designed to help farmers because the United States was primarily a rural, agrarian nation well into the 20th century. Much research focused on crop science and development of new varieties. As immigration and urbanization began to change American society, eugenics arose as a “scientific” approach viii ChapterFo r e w oTitle r d to cure the social problems such as poverty, overcrowding, and crime. Eu- genics serves as a good example as it was embraced by many of the country’s intellectuals at the time, and their decisions created a legacy that casts a dark shadow over bioethics in the 21st century. As the promises of the Human Genome Project become closer to reality and scientists identify the genes re- sponsible for specific and treatable conditions, those highly concerned with bioethics will continue to question the morality of rearranging the building code of life. The biotechnology debate has essentially settled into two opposing sides, with rather extreme positions prevalent in both. On the advocacy side are the proponents, perhaps best exemplified by Ronald Bailey in his book Liberation Biology: The Scientific and Moral Case for the Biotech Revolution. This book eloquently describes the benefits of biotechnology: curing diseases and disabilities for millions of sufferers, producing more nutritious food with less damage to the natural environment, enhancing human physical and intellectual capacities, and retarding the onset of the ravages of old age—all of which are at least possible in the not-too-distant future. Bailey aims to use biotechnology to dramatically boost people’s physical and intellectual capacities, eradicate diseases and cancers, restore the natural environment, and make death optional. Opposing the advocates is best expressed by Fritz Allhoff